Endoscopic remission · patients with induction of remission in ulcerative colitis
It is very uncertain whether LMWH changes endoscopic remission compared with placebo (very low certainty).
1 finding from 1 review
Endoscopic remission · patients with induction of remission in ulcerative colitis
It is very uncertain whether LMWH + standard therapy changes endoscopic remission compared with standard therapy (very low certainty).
1 finding from 1 review
Endoscopic remission · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide 10 mg changes endoscopic remission compared with prednisolone 40 mg (very low certainty).
1 finding from 1 review
Endoscopic remission · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg probably leads to higher endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
Endoscopic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA showed no clear difference in endoscopic remission compared with oral 5‐ASA (low certainty).
1 finding from 1 review
Endoscopic remission · Adult patients with active ulcerative colitis
Budesonide showed no clear difference in endoscopic remission (EI ≤ 1) compared with mesalamine (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in failure to induce endoscopic remission compared with conventional dosing (high certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower failure to induce endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce endoscopic remission compared with placebo (high certainty).
1 finding from 1 review
Induction of endoscopic remission in CD · Patients with active Crohn's disease
1 finding from 1 review
Failure to maintain endoscopic remission · Participants with Crohn's disease in remission
Adalimumab probably leads to lower failure to maintain endoscopic remission compared with placebo (moderate certainty).
1 finding from 1 review
Failure to maintain endoscopic remission · People with quiescent Crohn's disease (ileocolic resection)
It is very uncertain whether adalimumab changes failure to maintain endoscopic remission compared with active comparator (very low certainty).
1 finding from 1 review
Failure to maintain endoscopic remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain endoscopic remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maintenance of endoscopic remission in CD · Participants with Crohn's disease in remission
1 finding from 1 review
Failure to induce endoscopic remission · patients with induction of remission in ulcerative colitis
Etrolizumab showed no clear difference in failure to enter endoscopic remission at week 6 compared with placebo (moderate certainty).
2 findings from 1 review
Induction of endoscopic remission in UC at longest · people with active UC
Fecal microbiota transplantation showed no clear difference in induction of endoscopic remission in UC at longest compared with control (low certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to lower failure to maintain clinical or endoscopic remission compared with placebo (high certainty).
1 finding from 1 review